| Popis: |
Krithika Rajagopalan,1 Lisa Bloudek,2 Jessica Marvel,3 Carole Dembek,1 Abhishek Kavati3 1Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA; 2Curta Inc., Seattle, WA 98116, USA; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA Background: Indacaterol 27.5 µg/glycopyrrolate 15.6 µg (IND/GLY 27.5/15.6 µg) inhalation powder, a twice-daily, fixed-dose combination of a long-acting beta2-agonist (LABA) and a long-acting antimuscarinic antagonist (LAMA), is indicated in the US for long-term maintenance treatment of airflow obstruction in patients with COPD. The safety and efficacy of IND/GLY 27.5/15.6 µg have been established, but cost-effectiveness is not yet known. This study compared the cost-effectiveness of IND/GLY 27.5/15.6 µg with other long-acting COPD maintenance therapies. Methods: A Markov model was constructed from the US payer perspective. Health states were defined as mild (post-bronchodilator FEV1 ≥80% of predicted), moderate (50% ≤FEV1 |
